Time trends in the results of breast conservation in 4694 women

Fredriksson, Irma; Liljegren, Göran; Arnesson, Lars-Gunnar; Emdin, SO; Palm-Sjövall, M; Fornander, Tommy; Frisell, Jan; Holmberg, Lars

doi:10.1016/s0959-8049(01)00168-x

Cited by 28 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This risk difference was only found after 1991, and was statistically significant for the period 1996 -2000. Breast-conserving surgery became the treatment of choice for early breast cancer in Sweden during the 1980s, especially in areas with population-based screening (Fredriksson et al, 2001). The proportion of women receiving conservative surgery increased from 7% in 1980 to 51% in 1996 (Lindqvist et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening

2004

View full text Add to dashboard Cite

Sweden was the first country to establish a nationwide breast cancer screening service. We used the Swedish Family-Cancer Database to evaluate the risk of invasive carcinoma after in situ carcinoma of the breast. Risk estimates for contralateral and ipsilateral invasive malignancies following age and histology specific in situ breast carcinomas were calculated using Poisson's regression analysis. The agreement between concordant and discordant morphologies of invasive and in situ breast cancer was measured using the kappa statistic. Women with in situ breast cancer showed a relative risk of 2.03 for contralateral and 3.94 for ipsilateral invasive breast cancer. The risk was higher for in situ carcinomas diagnosed before the age of 50 years and after lobular in situ breast cancers. A comparison of the risks during the past decades suggested that the risk of ipsilateral breast cancer has increased in Sweden but that of contralateral breast cancer has remained unchanged. In situ and the subsequent invasive breast cancers did not seem to share their morphologies.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening

2004

View full text Add to dashboard Cite

show abstract

“…1 On the other hand, encouraging results with breast conserving surgery, in combination with adjuvant therapy, have led to the application of this treatment for larger tumours as well. 2 Currently, data from large follow up studies show local recurrence rates of approximately 5% for breast conserving surgery. 3 While there still is a higher risk of relapse compared with mastectomy, it is commonly acknowledged that the benefits of a less aggressive treatment approach outweigh the possibility of recurrent disease.…”

mentioning

confidence: 99%

c-mycAmplifications in primary breast carcinomas and their local recurrences

Aulmann

Adler²,

Rom³

et al. 2006

J Clin Pathol

View full text Add to dashboard Cite

Objective: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas. Methods: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation. Results: 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients. Conclusions: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.

show abstract

“…The number of patients managed with breast conserving treatment, including lumpectomy and radiotherapy, is on the rise [43,44], leading to increasing number of patients exposed to ionizing radiation. There is a non-significant increased risk of leukemia in BC patients who were treated with postoperative regional or breast radiotherapy (cumulative risk at 8 years: 0.89 and 0.44%; respectively) versus operation alone (P = 0.06 and 0.37; respectively) [27].…”

Section: Radiotherapy and Risk Of Shmmentioning

confidence: 99%

Secondary hematological malignancies following breast cancer treatment

Bayraktar

Escalón

2010

Oncol Rev

View full text Add to dashboard Cite

Breast cancer (BC) incidence has increased among women in most Western countries. Concurrently, the survival time of BC patients has increased with 5-year survival rates reaching 80-90%. Secondary hematological malignancies (SHM) following BC treatment are an issue of concern to clinicians and also to patients and their families. However, therapy-induced leukemia after BC is an underemphasized clinical problem. In this review, we will focus on the incidences and patterns of occurrence of SHM in patients with BC. We will address risk factors for the development of SHM and we will explore how secondary hematological malignancies impact the survival of BC patients.

show abstract

Time trends in the results of breast conservation in 4694 women

Cited by 28 publications

References 26 publications

Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening

Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening

c-mycAmplifications in primary breast carcinomas and their local recurrences

Secondary hematological malignancies following breast cancer treatment

Contact Info

Product

Resources

About